Stay updated on Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 is shown on the page. This is a minor internal update that does not affect study content or user-facing information, and To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedPublications section now states that entries are automatically filled from PubMed and may not all pertain to the study. Revision updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoved a funding-status disclaimer indicating potential delays due to government funding lapse; the page no longer displays operating status notes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check43 days agoChange DetectedThe screenshots show the same study page with identical core content including Study Overview, eligibility criteria, and locations; no substantive data or status changes are present. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedOverall, the page updates to announce a system status notice and a new software version (v3.2.0), removing the previous v3.1.0 reference.SummaryDifference1%

- Check79 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.